[{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"dab562b9-279d-4fe8-b2fc-7ee0c721ed02","acronym":"KUNPENG-2","url":"https://clinicaltrials.gov/study/NCT05989542","created_at":"2023-08-14T14:10:14.391Z","updated_at":"2025-02-25T16:40:06.600Z","phase":"Phase 3","brief_title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","source_id_and_acronym":"NCT05989542 - KUNPENG-2","lead_sponsor":"Beijing Pearl Biotechnology Limited Liability Company","biomarkers":" EGFR • KRAS • ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement","tags":["EGFR • KRAS • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • MET exon 14 mutation • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"6a19572d-9fdc-40c8-bddf-32eccbc29186","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808662","created_at":"2021-01-18T18:49:15.420Z","updated_at":"2025-02-25T16:31:44.180Z","phase":"Phase 2","brief_title":"Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung","source_id_and_acronym":"NCT03808662","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • HER-2 • ER • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["EGFR • HER-2 • ER • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-05"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"41be4368-ac8d-41a5-97f4-07c00abcbd42","acronym":"ADAPT-E","url":"https://clinicaltrials.gov/study/NCT04585477","created_at":"2023-03-02T18:01:37.004Z","updated_at":"2025-02-25T14:59:23.663Z","phase":"Phase 2","brief_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","source_id_and_acronym":"NCT04585477 - ADAPT-E","lead_sponsor":"Stanford University","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"02e83317-1e46-4ec1-8ee3-e88e0be802c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02321501","created_at":"2021-01-18T11:00:33.247Z","updated_at":"2024-07-02T16:34:27.615Z","phase":"Phase 1","brief_title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02321501","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-10"},{"id":"88c4d979-b2be-4f92-b3cd-f26a056f8d8f","acronym":"eVOLVE-Lung02","url":"https://clinicaltrials.gov/study/NCT05984277","created_at":"2023-08-09T14:09:39.751Z","updated_at":"2024-07-02T16:35:00.226Z","phase":"Phase 3","brief_title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05984277 - eVOLVE-Lung02","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • PD-L1 negative • ROS1 rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • PD-L1 negative • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2024-05-29"},{"id":"ebe23b1f-7731-46e6-a149-e9ae256b0616","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699123","created_at":"2021-01-19T20:50:06.440Z","updated_at":"2025-02-25T16:11:00.745Z","phase":"Phase 2","brief_title":"The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04699123","lead_sponsor":"Yale University","biomarkers":" EGFR • BRAF • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NC318"],"overall_status":"Recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 02/04/2021","start_date":" 02/04/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-24"},{"id":"3b1752ff-834a-4dfa-82f3-4a62af5d7fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761017","created_at":"2021-01-18T18:31:24.725Z","updated_at":"2024-07-02T16:35:04.675Z","phase":"Phase 1","brief_title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","source_id_and_acronym":"NCT03761017","lead_sponsor":"MacroGenics","biomarkers":" BRAF • ALK • MSI • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["BRAF • ALK • MSI • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lorigerlimab (MGD019)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"059c44d0-f5a3-4e0a-b39e-6b8103e251ad","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03833440","created_at":"2021-01-18T18:55:39.473Z","updated_at":"2024-07-02T16:35:06.100Z","phase":"Phase 2","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","source_id_and_acronym":"NCT03833440 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Orpathys (savolitinib) • ceralasertib (AZD6738) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 10/08/2019","start_date":" 10/08/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"b50ec11a-b0e6-466f-be8b-0ed2794b60be","acronym":"IOSI-LUNG-001","url":"https://clinicaltrials.gov/study/NCT04549428","created_at":"2021-01-18T21:45:24.870Z","updated_at":"2024-07-02T16:35:08.381Z","phase":"Phase 2","brief_title":"Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC","source_id_and_acronym":"NCT04549428 - IOSI-LUNG-001","lead_sponsor":"Oncology Institute of Southern Switzerland","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK fusion • ROS1 rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 01/23/2023","primary_completion_date":" 01/23/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-22"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"9f0a2252-2d03-40ea-9677-2060190e337e","acronym":"ARROS-1","url":"https://clinicaltrials.gov/study/NCT05118789","created_at":"2021-11-12T13:53:34.949Z","updated_at":"2024-07-02T16:35:15.663Z","phase":"Phase 1/2","brief_title":"A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","source_id_and_acronym":"NCT05118789 - ARROS-1","lead_sponsor":"Nuvalent Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zidesamtinib (NVL-520)"],"overall_status":"Recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-03-08"},{"id":"59cf1c76-20c0-482d-a704-e18624a0a2cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787613","created_at":"2023-03-28T14:05:08.783Z","updated_at":"2024-07-02T16:35:18.055Z","phase":"Phase 2","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","source_id_and_acronym":"NCT05787613","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ROS1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • ROS1 rearrangement • LAG3 expression","tags":["PD-L1 • ROS1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ROS1 rearrangement • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-22"},{"id":"49bd229e-a7a9-42f3-9559-2510a8eb6543","acronym":"LUN 17-139","url":"https://clinicaltrials.gov/study/NCT03786692","created_at":"2021-01-18T18:43:52.417Z","updated_at":"2024-07-02T16:35:19.761Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC","source_id_and_acronym":"NCT03786692 - LUN 17-139","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-12"},{"id":"77fe0c19-ea57-4747-8575-926fa32a925b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03377023","created_at":"2021-01-18T16:39:56.672Z","updated_at":"2024-07-02T16:35:22.265Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer","source_id_and_acronym":"NCT03377023","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/02/2018","start_date":" 02/02/2018","primary_txt":" Primary completion: 11/28/2024","primary_completion_date":" 11/28/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"},{"id":"6d847628-818f-4e1d-8da1-c3a365e4c09c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04621188","created_at":"2021-01-19T20:34:31.159Z","updated_at":"2024-07-02T16:35:25.732Z","phase":"Phase 2","brief_title":"Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)","source_id_and_acronym":"NCT04621188","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/19/2021","start_date":" 03/19/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-12-19"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"},{"id":"ec23150c-3a59-4217-b9f8-cffd1800bb21","acronym":"","url":"https://clinicaltrials.gov/study/NCT03299088","created_at":"2021-01-18T16:17:56.278Z","updated_at":"2025-02-25T15:53:53.407Z","phase":"Phase 1","brief_title":"Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations","source_id_and_acronym":"NCT03299088","lead_sponsor":"University of California, Davis","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/26/2018","start_date":" 06/26/2018","primary_txt":" Primary completion: 01/28/2021","primary_completion_date":" 01/28/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-09-22"},{"id":"a368028e-686f-48d5-a817-2e4343d80bdf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712877","created_at":"2021-01-19T20:52:47.325Z","updated_at":"2024-07-02T16:35:37.428Z","phase":"","brief_title":"Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers","source_id_and_acronym":"NCT04712877","lead_sponsor":"Lung Cancer Mutation Consortium","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2023-09-12"},{"id":"b9d29ac1-22f0-48b2-a031-d017175875c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914116","created_at":"2023-06-22T19:11:45.274Z","updated_at":"2024-07-02T16:35:37.381Z","phase":"Phase 1/2","brief_title":"A Study of DB-1311 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05914116","lead_sponsor":"DualityBio Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT324"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-09-12"},{"id":"8aea6752-9081-4156-8036-1fa904135caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05935774","created_at":"2023-07-07T14:09:36.968Z","updated_at":"2024-07-02T16:35:38.985Z","phase":"Phase 2","brief_title":"OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05935774","lead_sponsor":"University of Washington","biomarkers":" HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK","pipe":" | ","alterations":" BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • trabedersen (OT-101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2023-08-25"}]